NuGene International Receives Favorable Product Affirmations from Leading Southern California Spa and from International Celebrity Brande Roderick
IRVINE, Calif., Oct. 5, 2015 /PRNewswire/ — NuGene International, Inc. (“NuGene”) (NUGN), a developer, manufacturer and marketer of advanced skin and hair care lines utilizing adipose derived human stem cells and stem cell media, announced today that it recently received glowing reviews of its product lines from Contour Medical Spa in Hermosa Beach and international celebrity Brande Roderick.
Contour Medical Spa, established by Jennifer Baker in Hermosa Beach in conjunction with one of Beverly Hills’ top plastic surgeons, exclusively promotes NuGene’s products to customers and clients at Contour. Contour’s practice, according to Ms. Baker, has grown since 2008, when Contour was established, to a current patient count exceeding 7,000. Ms. Baker, who is a registered nurse, is also a clinical advisor and educator for Suneva Pharmaceuticals, an international pharmaceutical company specializing in dermal fillers and cosmeceuticals.
Ms. Baker uses NuGene’s products in their procedures at Contour and recently stated, “The NuGene stem cell product line has dramatically improved the effectiveness of our office-based procedures. Contour Medical Spa is thrilled to offer this revolutionary product line to our patients. NuGene stem cell serum used after the Micro Needling procedure has rapidly become the most requested and performed procedure at Contour. The micro needle device utilizes specialized micro needles in a small sterile cartridge to create micro perforations into the epidermis and the top layer of the dermis. As a result, the skin performs its natural repair mechanism enhanced by the NuGene stem cell formula. This procedure has yielded exceptional results rivaling many office-based laser procedures.”
Brande Roderick, television actress, model and a recent recipient of the Micro Needling procedure further endorsed the results she observed with NuGene stem cell serum stating, “Since I started using the NuGene products, I’ve noticed my skin looks and feels younger. I have experienced softened lines and a smoother texture. I’ve received lots of compliments from people I’ve known for a very long time about how much better my skin looks now than it did when I was in my 20’s. I would recommend NuGene products to any woman who wants her skin to look better and more youthful.”
“Micro Needling has become one of the most requested skin care treatments in recent years and its popularity is skyrocketing,” said Dr. Fady Elias, Director of Professional Business Development for NuGene. “We believe that NuGene offers the ideal product that can augment and enhance this type of skin treatment using our proprietary stem cell media. Our product can be taken home and used on a continuous basis after the procedure to further enhance the effects.”
About NuGene International, Inc.
NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the “next evolution of medical treatments.” The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Service Global Cosmeceuticals Market report. NuGene’s cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene’s exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has four patents pending covering 15 unique applications. NuGene’s goal is to leverage its knowledge and expertise to develop age defying cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform. For more information on NuGene and its stem cell product lines visit www.nugene.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the “safe harbor” created by those sections. All statements in this release that are not based on historical fact are “forward looking statements.” These statements may be identified by words such as “estimates,” “anticipates,” “projects,” “plans,” “proposes” or “planned,” “seeks,” “may,” “will,” “expects,” “intends,” “believes,” “should,” “would,” “could” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that NuGene expects or anticipates will occur in the future are forward-looking statements. While management has based any forward looking statements included in this release on its current expectations, we operate in a complex and changing domestic and international competitive environment where new and unanticipated risks may arise, and consequently the information on which such expectations were based, such as expectations of distributor product placements and sales, timing of planned and anticipated product deliveries or product introductions, may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors, including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Quarterly Report on Form 10-Q as filed on August 12, 2015 and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Investor/ Media Relations: